Tima Peterson
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,975, more than ten times the $107 reported in 2021.
Across 114 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$330
- Bristol Myers Squibb$298
- Merck$192
- Bayer$166
- Eisai Inc.$126
- Novartis$122
- plus $2K from 31 others
What the payments were for
- Food & beverage$2,73497%
- Education$783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $330 |
| Bristol Myers Squibb | 9 | $298 |
| Merck | 8 | $192 |
| Bayer | 8 | $166 |
| Eisai Inc. | 6 | $126 |
| Novartis | 6 | $122 |
| Jazz Pharmaceuticals Inc. | 4 | $121 |
| Johnson & Johnson | 6 | $113 |
| GSK | 5 | $108 |
| Nestle Healthcare Nutrition Inc. | 1 | $107 |
| Incyte Corporation | 3 | $82 |
| Lilly USA, LLC | 3 | $81 |
| Seagen Inc. | 1 | $78 |
| Pfizer | 3 | $77 |
| Daiichi Sankyo Inc. | 3 | $74 |
| AbbVie | 3 | $61 |
| EMD Serono, Inc. | 3 | $60 |
| Kyowa Kirin, Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Genentech USA, Inc. | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Novocure Inc. | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $39 |
| Iovance Biotherapeutics, Inc. | 2 | $35 |
| Legend Biotech USA Inc. | 2 | $32 |
| Genmab U.S., Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Immunocore Limited | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Geron Corporation | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Array Biopharma Inc | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,812 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 31 | $377 |
| Losartan Potassium | 18 | $265 |
| Hydromorphone Hcl | 11 | $250 |
| Morphine Sulfate | 14 | $170 |
Paid to pharmacies, not to this prescriber.
Other family in Ocala
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.